Post a Free Blog

Submit A Press Release

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
Action
Animation
ATP Tour (ATP)
Auto Racing
Baseball
Basketball
Boxing
Breaking News
Business
Business
Business Newsletter
Call of Duty (CALLOFDUTY)
Canadian Football League (CFL)
Car
Celebrity
Champions Tour (CHAMP)
Comedy
CONCACAF
Counter Strike Global Offensive (CSGO)
Crime
Dark Comedy
Defense of the Ancients (DOTA)
Documentary and Foreign
Drama
eSports
European Tour (EPGA)
Fashion
FIFA
FIFA Women’s World Cup (WWC)
FIFA World Cup (FIFA)
Fighting
Football
Formula 1 (F1)
Fortnite
Golf
Health
Hockey
Horror
IndyCar Series (INDY)
International Friendly (FRIENDLY)
Kids & Family
League of Legends (LOL)
LPGA
Madden
Major League Baseball (MLB)
Mixed Martial Arts (MMA)
MLS
Movie and Music
Movie Trailers
Music
Mystery
NASCAR Cup Series (NAS)
National Basketball Association (NBA)
National Football League (NFL)
National Hockey League (NHL)
National Women's Soccer (NWSL)
NBA Development League (NBAGL)
NBA2K
NCAA Baseball (NCAABBL)
NCAA Basketball (NCAAB)
NCAA Football (NCAAF)
NCAA Hockey (NCAAH)
Olympic Mens (OLYHKYM)
Other
Other Sports
Overwatch
PGA
Politics
Premier League (PREM)
Romance
Sci-Fi
Science
Soccer
Sports
Sports
Technology
Tennis
Thriller
Truck Series (TRUCK)
True Crime
Ultimate Fighting Championship (UFC)
Uncategorized
US
Valorant
Western
Women’s National Basketball Association (WNBA)
Women’s NCAA Basketball (WNCAAB)
World
World Cup Qualifier (WORLDCUP)
WTA Tour (WTA)
Xfinity (XFT)
XFL
0
-- Advertisement --spot_img
HomeBusinessWhat to Expect From HCA Healthcare’s Upcoming Earnings Results?

What to Expect From HCA Healthcare’s Upcoming Earnings Results?

Add to Favorite
Added to Favorite


Oppenheimer analysts provided their outlook on HCA Healthcare, Inc’s (NYSE:HCA) upcoming Q2 earnings, expecting the company to post an adjusted EBITDA of $2.775 billion (vs. Street’s $2.809 billion), adjusted EPS of $3.69 (vs. Street’s $3.70) and revenue of $15 billion (vs. Street’s $60.4 billion).
On June 30, the company pre-announced Q2 results and lowered 2022 guidance due to a muted rebound in non-COVID volumes and persistent labor pressures. Based on the industry backdrop, the analysts believe expectations are fairly muted for Q2. Furthermore, they believe a potential recession could stoke fears around higher bad debt and weaker elective procedures. Nevertheless, the analysts think that the company is attractively valued and remain confident that it will operationally outperform its peers. The analysts maintained their outperform rating and $255 price target.

Subscribe to get Latest News Updates

Latest News

You may like more
more

Wheaton Precious Metals Corp. (NYSE:WPM) Financial Overview

Earnings Per Share (EPS) for Q3 2024 stood at...

NRG Energy, Inc. (NYSE:NRG) Stock Price Target Shows Positive Trend

The consensus price target for NRG Energy, Inc. (NYSE:NRG)...

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Overview

The consensus price target for Xeris Biopharma's stock has...